ArticlePhysics and imaging in radiation oncology2025
Multiomic random forest toxicity modeling of radiation esophagitis.
Article in Physics and imaging in radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SHAP-based interpretable machine learning with longitudinal delta-radiomics across seven weeks of treatment for xerostomia prediction in head-and-neck cancer.Radiation oncology (London, England) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Radiation esophagitis (RE) is a major dose-limiting toxicity resulting from radiotherapy for non-small-cell lung cancer (NSCLC). Multiomic features may provide additional predictive value for high-grade RE compared to traditionally used clinical and dose-volume histogram (DVH) parameters. We aimed to investigate the utility of multiomic features in improving RE toxicity prediction models. Materials and methods: Of the 179 NSCLC patients considered, 27 patients (15.08 %) were found to have toxicity ≥grade 3 RE per CTCAE v5.0. A total of 343 CT- and PET- based radiomic and dosiomic features were extracted. Four toxicity prediction models were created using clinical factors and features from one of the following groups: (a) base model (DVH), (b) radiomic, (c) dosiomic, and (d) combined radiomic and dosiomic. Models were developed using a random forest classifier with 100 Monte Carlo cross-validation iterations and an 80 %/20 % training/test split. Model predictive performance was evaluated by area under the receiver operating characteristic curve (AUC) and area under the precision-recall curve (AUPRC). Results: The AUC and AUPRC values (mean ± standard deviation) for the 4 model types were 0.69 ± 0.10/0.42 ± 0.12 (base model), 0.71 ± 0.12/0.48 ± 0.13 (radiomic), 0.73 ± 0.10/0.48 ± 0.15 (dosiomic), and 0.75 ± 0.10/0.49 ± 0.14 (radiomic and dosiomic), respectively. The bootstrap percentile method, which was used to compare performance metrics between multiomic and base models, showed that the combined model was the best performing model type. Conclusion: All multiomic models outperformed the base model. The combined radiomic-dosiomic model provides novel insights into high-grade RE risk and may inform future strategies for toxicity mitigation and personalized treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.